Publications
5808 Results
- Journal / Conference
- San Antonio Breast Cancer Symposium (Dec 4-8, 2018, San Antonio, TX), poster, P1-17-03
- Year
- 2018
- Research Committee(s)
- Breast
- Study Number(s)
- S0307
Statin use, site of recurrence, and survival among post-menopausal women taking bisphosphonates as adjuvant therapy for primary breast cancer (SWOG S0307)
- Journal / Conference
- Annals of Oncology, Vol 29, Issue suppl_8, 1; ESMO 2018 Congress (October 19-23, Munich, Germany), poster
- Year
- 2018
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel
- Journal / Conference
- Blood 132:3978; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106, S1203, SWOG-8600, SWOG-9031, SWOG-9333
2nd Cycle Remission Achievement with 7+3 is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials
- Journal / Conference
- Blood 132:929; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), oral
- Year
- 2018
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0816
Long-term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-adapted Approach
- Journal / Conference
- Blood 132:2927; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0816
Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling of SWOG S0816 with receiver operating characteristic analysis
- Journal / Conference
- Blood 132:309; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), oral
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/C10701
A phase II study of dasatinib and dexamethasone as primary therapy followed by hematopoietic cell transplantation for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: CALGB Study 10701 (Alliance)
- Journal / Conference
- Blood 132:1386; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), accepted, poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106
Event-free Survival as a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-level Analysis of Multiple Randomized Trials (Alliance A151614)
- Journal / Conference
- Blood 132:1403; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- S1203
Predicting Non-Fatal Toxicities with 7+3 Induction Chemotherapy in Adult Acute Myeloid Leukemia: Analysis of SWOG Trial S1203
- Journal / Conference
- Blood 132:1992; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster
- Year
- 2018
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0777
Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 with Long-Term Follow Up
- Journal / Conference
- Blood 132:437; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), accepted, oral/plenary
- Year
- 2018
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E2906